This site uses cookies to provide you with a more responsive and personalized service. By using this site you agree to our use of cookies. Please read our cookie policy for more information on the cookies we use and how to delete or block them.

Ok, Got It
News, stories and opinions for the business innovators of the world.

Lumos Diagnostics raises AU$25m in oversubscribed capital raise

Suraya SalehMarketing Communications Manager

Lumos Diagnostics, a rapid point-of-care diagnostics company spun out of Planet Innovation, has closed an oversubscribed AU$25 million capital raise.

The funding will enable Lumos to continue to build its high-growth rapid diagnostics business, including expanding manufacturing operations in California and Florida and continuing commercial growth of its FebriDx® product, a world-first finger prick blood test that can indicate if a person has a bacterial or viral infection within 10 minutes.

The capital was raised from a combination of institutional funds, including Perennial Value and Ellerston Capital, and sophisticated investors, many of whom have backed Lumos through previous capital raises. It follows on from a successful Series A raise in early 2020 led by Planet Innovation.

“Lumos has built a strong foundation over the past few years, and this funding will enable us to accelerate our growth plan,” said Sam Lanyon, executive chair of Lumos Diagnostics. “We’re delighted that investors recognize how unique Lumos is with its suite of rapid diagnostic digital solutions coupled with high-impact and globally relevant proprietary products such as FebriDx.”

David Keelan, Portfolio Manager at Ellerston Capital and a first-time Lumos investor, said: “I’m really excited by Lumos’s potential. Rapid diagnostics is a developing sector internationally, and to have a really strong and growing service business, complemented by a product business with huge potential – it was too good an investment to pass up.”

Ryan Sohn, Deputy Portfolio Manager at Perennial Value, was introduced to Lumos Diagnostics through Planet Innovation, where he is also an investor. “Through PI, I’ve been able to track Lumos’s substantial growth over the past few years. It’s a company with great ambition and a great team behind it, and I’m excited to be a part of this next phase of growth,” Ryan said.

While many businesses have been negatively impacted by the devastating global impacts of the COVID-19 crisis, Lumos was well positioned to quickly respond and has subsequently experienced growth across both its service and product businesses. On the service side, Lumos has secured several contracts to develop and manufacture next generation rapid SARS-CoV-2 tests. On the product side, the UK’s National Institute of Health Research (NIHR) has demonstrated real-world use of the FebriDx test as a frontline triage tool to help healthcare workers manage suspected COVID-19 infected patients. The FebriDx test was featured in a UK Medtech Innovation Briefing (MIB), addressing the impact that the FebriDx test can have on the concurrent COVID-19 pandemic and antimicrobial resistance global health crises. Also, FebriDx may be used as an important risk assessment tool for safe workplaces and is currently being piloted in aged care and other professional use settings continuing to operate during the pandemic.

Robert Sambursky, MD, president and CEO for Lumos Diagnostics, said the capital raise would enable Lumos to expand its commercial operations dedicated to both the continued development of rapid point-of-care diagnostics and meet the need for innovative testing solutions to help address the global COVID-19 pandemic.

“The unique ability of the FebriDx test to identify patients as viral or bacterial within 10 minutes helps guide clinical decision making – whether that is isolation for those identified as having a virus, antibiotic prescriptions for bacterial infections, or simply reassurance that an infection is not present. These actionable results make FebriDx the ideal front-line triage test for patients presenting with acute respiratory illness symptoms (sore throat, cough, shortness of breath) consistent with COVID-19 and an ideal tool for rapid deployment in any future pandemics,” Sambursky said.

FebriDx is CE marked for sale in Europe and is also registered or licensed with the following other health authorities: Health Canada, Australia TGA, Saudi Arabia FDA, Pakistan DRAP, Singapore HSA, and Malaysia MoH. While FebriDx is not yet commercially available in the United States, Lumos Diagnostics has both ongoing and historic prospective, multicenter U.S. clinical trials and anticipates U.S. Food and Drug Administration (FDA) clearance.

Blackpeak Capital acted as Financial Advisor to Lumos and Joint Lead Manager for the raising alongside Canaccord Genuity.

SHARE THIS ARTICLE:
Suraya Saleh Marketing Communications Manager

Suraya is the Marketing Communications Manager at Planet Innovation. A former journalist, Suraya is passionate about telling engaging stories for brands that have a positive impact on the world.

Topics.

Sign up for the Perspectives newsletter:

A roundup of the latest news and opinions from PI.

Related Articles.

Lumos Diagnostics merges with RPS Diagnostics

News

Lumos Diagnostics and RPS Diagnostics have merged to create a full-service point-of-care diagnostic development company and support the international commercialization of FebriDx.

PI backs Lumos Diagnostics with $20m Series A investment

News

Planet Innovation has agreed to a $A20 million strategic investment in Lumos Diagnostics, a rapid point-of-care diagnostics company.

PI and Lumos pick up top Medical Design and Engineering Awards for rapid diagnostic development platform

Design

Planet Innovation and Lumos Diagnostics have won two awards at the 2020 Good Design Awards, including a Good Design Award Gold accolade for Lumos’s Leelu Reader.

Tackling the global health threat of antibiotic resistance through Lumos Diagnostics and the FebriDx test

Diagnostics

November 18-24 is World Antibiotic Awareness Week, so it’s a good time to draw attention to the global health challenge of antibiotic resistance, which Planet Innovation is combating through its business Lumos Diagnostics.

News

Lumos Diagnostics merges with RPS Diagnostics

Lumos Diagnostics and RPS Diagnostics have merged to create a full-service point-of-care diagnostic development company and support the international commercialization of FebriDx.